火傷(Burns)：世界の治験レビュー（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Burns 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Burns to Dermatology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Burns to Dermatology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Burns 25
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Burns Therapeutics Clinical Trials 32
Prominent Drugs 33
Latest Clinical Trials News on Burns 34
May 04, 2015: Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 34
Apr 29, 2015: Poster Presentation Highlighting NexoBrid Awarded Best-in-Category in Wound Care Practice at the American Burn Association 47th Annual Meeting 34
Apr 23, 2015: Cytori Reports Preclinical and Mechanistic Data Supporting Use of Cytori Cell Therapy in Wounds Combining Thermal Burn and Radiation Exposure 35
Apr 21, 2015: MediWound’s NexoBrid Highlighted in Presentations at the 2015 American Burn Association 47th Annual Meeting 36
Apr 20, 2015: MediWound Initiates U.S. Phase 3 Trial With NexoBrid to Treat Severe Burns 36
Clinical Trial Profiles 38
Clinical Trial Overview of Top Companies 38
MediWound Ltd. 38
Clinical Trial Overview of MediWound Ltd. 38
Fibrocell Science, Inc. 39
Clinical Trial Overview of Fibrocell Science, Inc. 39
Sun Pharmaceutical Industries Limited 40
Clinical Trial Overview of Sun Pharmaceutical Industries Limited 40
Stemnion, Inc 41
Clinical Trial Overview of Stemnion, Inc 41
Bayer AG 42
Clinical Trial Overview of Bayer AG 42
HealOr Ltd. (Inactive) 43
Clinical Trial Overview of HealOr Ltd. (Inactive) 43
GCP-Service International Ltd. & Co. KG 44
Clinical Trial Overview of GCP-Service International Ltd. & Co. KG 44
CoDa Therapeutics, Inc. 45
Clinical Trial Overview of CoDa Therapeutics, Inc. 45
BioMarin Pharmaceutical Inc. 46
Clinical Trial Overview of BioMarin Pharmaceutical Inc. 46
Baxter International Inc. 47
Clinical Trial Overview of Baxter International Inc. 47
Clinical Trial Overview of Top Institutes / Government 48
University of Texas Medical Branch at Galveston 48
Clinical Trial Overview of University of Texas Medical Branch at Galveston 48
Massachusetts General Hospital 49
Clinical Trial Overview of Massachusetts General Hospital 49
Shiraz University of Medical Sciences 50
Clinical Trial Overview of Shiraz University of Medical Sciences 50
Shriners Hospitals for Children 51
Clinical Trial Overview of Shriners Hospitals for Children 51
Tehran University of Medical Sciences 52
Clinical Trial Overview of Tehran University of Medical Sciences 52
U.S. Army Institute of Surgical Research 53
Clinical Trial Overview of U.S. Army Institute of Surgical Research 53
Association of Dutch Burn Centres 54
Clinical Trial Overview of Association of Dutch Burn Centres 54
National Institute of General Medical Sciences 55
Clinical Trial Overview of National Institute of General Medical Sciences 55
University of Zurich 56
Clinical Trial Overview of University of Zurich 56
Changhai Hospital 57
Clinical Trial Overview of Changhai Hospital 57
Five Key Clinical Profiles 58
Appendix 80
Abbreviations 80
Definitions 80
Research Methodology 81
Secondary Research 81
About GlobalData 82
Contact Us 82
Disclaimer 82
Source 82